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Objective: Type 1 diabetes is characterized by autoimmune destruction of b-cells leading to severe insulin deﬁciency. Although many im-
provements have been made in recent years, exogenous insulin therapy is still imperfect; new therapeutic approaches, focusing on preserving/
expanding b-cell mass and/or blocking the autoimmune process that destroys islets, should be developed. The main objective of this work was to
test in non-obese diabetic (NOD) mice, which spontaneously develop autoimmune diabetes, the effects of local expression of Insulin-like growth
factor 1 (IGF1), a potent mitogenic and pro-survival factor for b-cells with immunomodulatory properties.
Methods: Transgenic NOD mice overexpressing IGF1 speciﬁcally in b-cells (NOD-IGF1) were generated and phenotyped. In addition, miRT-
containing, IGF1-encoding adeno-associated viruses (AAV) of serotype 8 (AAV8-IGF1-dmiRT) were produced and administered to 4- or 11-
week-old non-transgenic NOD females through intraductal delivery. Several histological, immunological, and metabolic parameters were
measured to monitor disease over a period of 28e30 weeks.
Results: In transgenic mice, local IGF1 expression led to long-term suppression of diabetes onset and robust protection of b-cell mass from the
autoimmune insult. AAV-mediated pancreatic-speciﬁc overexpression of IGF1 in adult animals also dramatically reduced diabetes incidence, both
when vectors were delivered before pathology onset or once insulitis was established. Transgenic NOD-IGF1 and AAV8-IGF1-dmiRT-treated NOD
animals had much less islet inﬁltration than controls, preserved b-cell mass, and normal insulinemia. Transgenic and AAV-treated islets showed
less expression of antigen-presenting molecules, inﬂammatory cytokines, and chemokines important for tissue-speciﬁc homing of effector T
cells, suggesting IGF1 modulated islet autoimmunity in NOD mice.
Conclusions: Local expression of Igf1 by AAV-mediated gene transfer counteracts progression to diabetes in NOD mice. This study suggests a
therapeutic strategy for autoimmune diabetes in humans.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Type 1 diabetes (T1D) results from the progressive autoimmune
destruction of b-cells that ultimately leads to insulin deﬁciency and
overt hyperglycemia. Patients with T1D require lifelong insulin
replacement therapy to survive. Despite the improvements in insulin
formulation and delivery, glycemic control is imperfect with this
treatment, and patients are at high risk of suffering potentially life-
threatening hypoglycemia episodes or, due to chronic exposure to
hyperglycemia, developing serious microvascular, macrovascular, and
neurological complications with high morbidity and mortality. Islet
transplantation has also shown therapeutic beneﬁt in humans. The
broad application of this approach, however, is limited by the shortage
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develop novel, more efﬁcacious treatments. Gene therapy can
circumvent these limitations and help maintain the endogenous b-cell
mass and, therefore, physiologic insulin secretion, by enabling the
expression of key factors that protect b-cells from the autoimmune
attack.
Insulin-like growth factor 1 (IGF1) is a b-cell mitogen and pro-survival
factor that has also been reported to play important roles in b-cell
maturation and function [2]. Additionally, IGF1 regulates immune
functions and is one of the main players in the crosstalk between the
endocrine and immune systems [3,4]. Pre-clinical therapeutic strate-
gies based on multiple administrations of recombinant IGF1 [5e7] or
plasmid-mediated hepatic overexpression of IGF1 [8] reduce the
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administration of recombinant IGF1 to humans improves glycemic
control both in type 1 [9e12] and type 2 diabetic patients [13,14].
However, therapeutic efﬁcacy was not sustained after withdrawal of
IGF1 treatment [10,11].
Previously, we demonstrated that IGF1 overexpression in b-cells of
transgenic mice counteracts the cytotoxic effects of streptozotocin
(STZ) and promotes b-cell regeneration in a genetic background-
independent manner [15,16]. Moreover, IGF1 overexpression in b-
cells also prevented islet inﬁltration and immune cell-mediated b-cell
death in transgenic mice that overexpress human interferon-b (IFN-b)
in b-cells [17]. IFN-b mice have chronic insulitis and develop auto-
immune diabetes upon administration of very low doses of STZ [17].
Despite this solid evidence supporting the protective role of IGF1 on
diabetes induction, the fair argument was raised that the effects of
IGF1 had not been tested in the context of spontaneous autoimmune
diabetes. In addition, it remained to be demonstrated if the protection
against diabetes mediated by IGF1 was due to the expression of the
growth factor during embryonic development and early postnatal life
and if the same protection would be achieved if IGF1 was expressed in
an adult animal.
In vivo gene transfer of therapeutic candidate genes through adeno-
associated viral (AAV) vectors may offer the possibility of lifelong
beneﬁcial effects after a one-time treatment, as the production of
therapeutic proteins for extended periods of time after a single
administration of these vectors has repeatedly been demonstrated in
several animal models and in humans [18,19]. AAV vectors are pre-
dominantly non-integrative vectors that efﬁciently transduce dividing
and non-dividing cells in vivo in a wide range of animal and human
tissues with low toxicity and immunogenicity [18]. Several naturally-
occurring and engineered serotypes exist which exhibit differential
tissue tropism, and we and others have previously demonstrated the
feasibility of efﬁcacious gene transfer to the pancreas of small animals
with AAV vectors of serotypes 8 and 9 [20e25]. Moreover, incorpo-
ration of microRNA target sequences (miRTs) in the AAV expression
cassette has recently been shown to enable tissue-speciﬁc transgene
expression [26,27], opening the door to sophisticated ways of regu-
lation of vector tropism.
In this work, we have tested the effects of local expression of IGF1 in
non-obese diabetic (NOD) mice that spontaneously develop the disease
and share many genetic and immunopathogenic features with human
T1D [28]. First, we generated transgenic NOD mice overexpressing
IGF1 in b-cells and demonstrated long-term suppression of diabetes
onset and robust protection of b-cell mass from the autoimmune
insult. Then we used miRT-containing, IGF1-encoding, AAV8 vectors to
show that pancreatic IGF1 expression in adult mice was sufﬁcient to
protect against diabetes onset in non-transgenic NOD mice through
blockage of b-cell-directed autoimmune attack. Our results highlight
the potential that a therapeutic strategy based on IGF1 gene transfer to
the pancreas may hold for the treatment of autoimmune diabetes in
humans.
2. MATERIAL AND METHODS
2.1. Animals
RIP-1/IGF1 transgenic mice of ICR genetic background [15] were
successively backcrossed with NOD/LtJ mice (originally from Charles
River) to generate a NOD-IGF1 transgenic colony. Heterozygous female
NOD-IGF1 mice of the N15 generation onwards (>99.99% NOD
background) were used to perform studies. Non-transgenic littermates
were used as controls. For AAV-mediated gene transfer studies, wild
type female NOD/Ltj mice were used. Mice were housed in speciﬁcMOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. This is an op
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diet (Harlan) ad libitum feeding. Mice were considered diabetic after
two consecutive blood glucose readings >250 mg/dL. AAV retrograde
pancreatic intraductal delivery was performed as previously [20]. All
experimental procedures were approved by the Ethics Committee for
Animal and Human Experimentation of Universitat Autònoma de
Barcelona.
2.2. AAV vector production
Single-stranded AAV vectors were generated by cloning the Green
Fluorescent Protein (GFP) or murine IGF1Ea propeptide (IGF1) coding
sequences under control of the ubiquitous CAG hybrid promoter (CMV
enhancer, chicken b-actin promoter) into AAV backbone plasmids.
When indicated, miRT-122a and miRT-1 sequences [27] were cloned
in the 30 untranslated region (UTR). AAV8 were produced by triple
transfection of HEK293 and puriﬁed by an optimized CsCl-based
gradient method that renders high purity vectors preps [29]. Vectors
were titered by quantitative PCR (qPCR).
2.3. Islet isolation and culture
Pancreata were intraductally perfused (Collagenase I/II (0.1 mg/mL)
and thermolysin) (Roche), diluted in M199 media (Thermo Scientiﬁc),
excised, and digested for 19 min at 37 C. Islets were puriﬁed by
gradient centrifugation on Histopaque-1077 (SigmaeAldrich) and
hand-picked under a stereomicroscope (Leica). When indicated, islets
were cultured at 37 C for 40 h in RPMI 1640 medium (7 mM glucose),
supplemented with 1% BSA, 2 mM glutamine, and penicillin/strepto-
mycin in an atmosphere of 95% humidiﬁed air, 5% CO2. After the
incubation period, islets were handpicked, and inﬁltrating immune
cells extruded from the islets were recovered after pelleting the culture
media and ﬁltering through a 30 mm PARTEC Cell Trics ﬁlter (#04-
0042-2316).
2.4. Hormone and metabolite assays
Glycemia was determined with Elite Glucometers (Bayer) after tail-
tip bleeding. To perform glucose tolerance test, awake mice were
fasted overnight (16 h) and administered with an intraperitoneal in-
jection of glucose (1 g/kg body weight). Insulin and IGF1 were
measured by ELISA (Crystal Chemical and Immunodiagnostic Systems,
respectively). Serum triglycerides and total cholesterol were quantiﬁed
spectrophotometrically using an enzymatic assay kit (Horiba-ABX).
Serum free fatty acids were measured by the acyl-CoA synthase and
acyl-CoA oxidase methods (Wako Chemicals GmbH). Serum b-
hydroxybutyrate was quantiﬁed by an enzymatic assay (Randox Lab).
All biochemical parameters were determined using Pentra 400
Analyzer (Horiba-ABX).
2.5. Immunohistochemistry
Tissues were ﬁxed in 4% formalin, embedded in parafﬁn, sectioned,
and incubated with the corresponding primary and secondary anti-
bodies (Supplemental Table 1). Hoechst (SigmaeAldrich) was used for
ﬂuorescent nuclear counterstaining. For brightﬁeld images, signal was
visualized with ABC-Peroxidase (Thermo Scientiﬁc) and 3,3-
diaminobenzidina (DAB) (Sigma) and counterstained in Mayer’s he-
matoxylin (Merk). TUNEL staining was performed following manufac-
turer’s instructions (Roche 1.684817). Images were obtained with a
Nikon Eclipse 90i microscope (Nikon). b-Cell mass, b-cell replication,
and insulitis score were determined as previously described [20]. For
histological islet size determination, the number of islets found per
pancreas (examined in three sections per individual, 150 mm apart
from each other) was distributed according to their insulin-positiveen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 665
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positive for TUNEL and negative for glucagon, somatostatin and
pancreatic polypeptide per islet (at least 300 islets per group were
analyzed). The number of Foxp3 positive cells/islet area was quantiﬁed
in all islets of two different pancreatic sections per mouse (at least 224
islets per group were analyzed).
2.6. Gene expression analysis
Total RNA was extracted from pancreas, liver, and heart using Tripure
Isolation Reagent (Roche) and Rneasy Mini Kit (Qiagen) and from
isolated islets with Rneasy Micro Kit (Qiagen). Total RNA was reverse-
transcribed with Transcriptor First Strand cDNA Synthesis Kit (Roche).
qPCR was performed in a LightCycler 480 II (Roche) using Light-
Cycler 480 SYBR Green I Master mix (Roche). Primer sequences are
listed in Supplemental Table 2. Results were analyzed using the
Pfafﬂ’s mathematical model [30] and values were normalized to mu-
rine Rplp0 expression. miRNA-enriched RNA was extracted using
miRVana miRNA Isolation Kit (Life Technologies). Ten nanograms of
RNA were reverse-transcribed with miRCURY LNA Universal RT
microRNA PCR e Universal cDNA synthesis kit II (Exiqon). Expression
was quantiﬁed by qPCR using ExiLENT SYBR Green Master mix
(Exiqon) relative to U6snRNA expression.
2.7. Vector genome copy number
Tissues were digested overnight in Proteinase K (0.2 mg/mL), and total
DNA was isolated with MasterPureDNA Puriﬁcation Kit (Epicentre
Biotechnologies). Vector genome copy numbers were determined in
20 ng of DNA by qPCR with primers and probe speciﬁc for vector-borne
polyA (Supplemental Table 2). A standard curve was built by serial
dilution of linearized plasmid bearing the target sequence spiked into
20 ng of non-transduced mouse genomic DNA.
2.8. Statistics
All values are expressed as mean  SEM. Statistical comparisons
were made using Student’s t-test or one-way analysis of variance
(ANOVA) and Tukey post-test. Statistical signiﬁcance was considered if
P < 0.05.
3. RESULTS
3.1. b-Cell overexpression of IGF1 suppresses diabetes in NOD
mice
We generated NOD transgenic mice overexpressing IGF1 in b-cells
(NOD-IGF1) by successive backcrossings (N ¼ 15) of transgenic mice
of ICR genetic background overexpressing IGF1 speciﬁcally in b-cells
[15] with NOD mice. NOD-IGF1 islets showed high levels of expression
and content of IGF1 (Figure 1A,B), which was limited to b-cells due to
the use of the Rat Insulin Promoter I (RIP-I) (Figure 1C). Despite the
high levels of expression of the transgene, NOD-IGF1 mice did not
show increased circulating levels of IGF1 (Figure 1D), in agreement
with previous observations of the same transgenic in other genetic
backgrounds [15,16].
To assess the effect of IGF1 overexpression on diabetes development in
the NOD model, blood glucose was monitored biweekly in female
transgenic and non-transgenic NOD mice up to 30 weeks of age
(Figure 1E). Animals were considered diabetic when two consecutive
blood glucose readings were>250 mg/dL. Only 3% of transgenic NOD-
IGF1 mice (1/32) developed hyperglycemia, as opposed to the 70% of
wild type NOD littermates (23/34) that became diabetic over the same
period of time (Figure 1F), indicating a clear protection from diabetes666 MOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. Thimediated by local IGF1. Approximately 30% of wild-type NODs never
became diabetic, as previously described [31]. Normoglycemia in NOD-
IGF1 mice was sustained by normal levels of circulating insulin, which
was undetectable at either 15 or 30 weeks of age in NOD mice that had
become hyperglycemic (Figure 2A). A glucose tolerance test performed
at 15 weeks of age, i.e. at the time of onset of hyperglycemia in the NOD
colony, showed that NOD-IGF1 mice and the NOD mice that had
remained normoglycemic (NG) presented indistinguishable fasting blood
glucose levels and responded similarly to a glucose overload, whereas
hyperglycemic (HG) NOD mice were glucose intolerant (Figure 2B).
Similar observations were made at 30 weeks of age (Figure 2C), indi-
cating that IGF1 helped maintain long-term glucose tolerance. More-
over, secondary to diabetes development, as soon as 15 weeks of age,
HG NOD mice had highly increased levels of serum triglycerides, free-
fatty acids and b-hydroxybutyrate. In contrast, NOD-IGF1 mice dis-
played normal levels of these metabolites (Figure 2D).
3.2. Preservation of b-cell mass in transgenic NOD-IGF1 mice
through reduced apoptosis
Pancreata from NOD and NOD-IGF1 mice were isolated and analyzed
at several ages to evaluate IGF1-mediated effects on b-cell mass. At 4
weeks of age, NOD-IGF1 mice had w2.5-fold greater b-cell mass
compared with NOD mice (Figure 3A,B). Such gain in b-cell mass was
due to an increased number of islets (Figure 3C) rather than an in-
crease in islet size (Supplemental Figure 1A). Double glucagon and
insulin immunostaining of pancreas sections showed NOD-IGF1 islets
had normal distribution of a and b endocrine cells, with glucagon-
expressing cells located in the periphery and insulin-expressing in
the core of the islet (Supplemental Figure 1B).
By 15 weeks of age,w20% of NOD mice had become hyperglycemic
(Figure 1F). In these animals, the b-cell mass was almost undetectable
(Figure 3D,E). In normoglycemic NOD mice, the b-cell mass was
preserved; islets, however, showed considerable inﬁltration
(Figure 3D,E). In contrast, islets from 15-week-old NOD-IGF1 mice
showed preserved b-cell mass and were mostly free of insulitis
(Figure 3D,E). Similar observations were made at 30 weeks of age
(Figure 3F,G), an age at which 70% of NOD mice had become diabetic
(Figure 1F), indicating that local overexpression of IGF1 mediated long-
term preservation of the b-cell mass also in the context of the auto-
immune NOD model.
In order to characterize which mechanism/s were responsible for the
maintenance of b-cell mass in NOD-IGF1 mice, b-cell replication, and
apoptosis were assessed at the prediabetic stage. In islets from 8-
week-old mice, we detected no differences in the expression of
several key regulators of the b-cell cycle, such as cyclin-dependent
kinase 4 (Cdk-4), cyclins D1 and D2, and the cyclin-dependent ki-
nase inhibitor 1B (p27) (Supplemental Figure 2AeD). In addition, we
found a moderate increase in the expression of cyclin-dependent ki-
nase inhibitor 1A (p21) (Supplemental Figure 2E), which is believed to
act as a molecular brake to mitogenic stimuli [32]. Consistent with this
expression data, no differences were found in the % of replicating b-
cells, as determined by double Insulin-Ki67 immunostaining
(Figure 3H). However, the TUNEL assay evidenced a marked decrease
in b-cell apoptosis in transgenic NOD-IGF1 islets compared with wild
type NOD islets (Figure 3I). These results indicated that while NOD
mice lost their b-cells, became glucose intolerant, and developed
hyperglycemia over time, IGF1 overexpression in the b-cells of
transgenic NOD-IGF1 mice was able to preserve b-cell mass and
functionality and protect from diabetes, mainly through a reduction in
the number of apoptotic b-cells.s is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: NOD-IGF1 mice that overexpress IGF1 in b-cells are protected against diabetes development. (A) Igf1 gene expression in islets (n ¼ 9e10/group). (B) IGF1
content in islet extracts (n ¼ 5e6/group). (C) Representative images of pancreatic sections immunostained for IGF1 (green) and insulin (red) (n ¼ 3/group). Original magniﬁcation
400 (scale bar: 50 mm). (D) Serum IGF1 levels (n ¼ 5/group). All determinations (AeD) were performed at the pre-diabetic stage (4e8 weeks of age). (E) Monitoring of glycemia
from 4 to 30 weeks of age in NOD (n ¼ 34) and NOD-IGF1 (n ¼ 32) mice. NG: normoglycemic. HG: hyperglycemic. (F) Cumulative incidence of diabetes over a period of 30 weeks
in NOD (n ¼ 34) and NOD-IGF1 (n ¼ 32) mice. Results are expressed as mean  SEM. *P < 0.05 vs. NOD. ND: Non-detected.
MOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
667
Figure 2: NOD-IGF1 mice have normal insulinemia and are glucose tolerant. (A) Serum insulin levels in fed conditions in normoglycemic (NG) and hyperglycemic (HG) NOD
mice and in NOD-IGF1 mice at 15 and 30 weeks of age (n ¼ 4e8/group). (B) Glucose tolerance test performed in 15-week-old NOD NG mice (n ¼ 5), in NOD HG mice (n ¼ 2) and
in NOD-IGF1 mice (n ¼ 8). (C) Glucose tolerance test performed in 30-week-old NOD NG mice (n ¼ 2) and NOD-IGF1 mice (n ¼ 9). (D) Serum concentrations of triglycerides, free-
fatty acids, and b-hydroxybutyrate in fed conditions at 15 weeks of age in all experimental groups (n ¼ 5/group). Results are expressed as mean  SEM. *P < 0.05 vs. NOD NG;
#P < 0.05 vs. NOD HG. ND: Non-detected.
Original Article3.3. Overexpression of IGF1 in b-cells halts the autoimmune attack
In NOD mice, the extent of intra-islet mononuclear cell inﬁltrates
(insulitis) correlates with the progression to autoimmune diabetes [33].
We then investigated whether IGF1-mediated modulation of islet
inﬁltration may contribute to the phenotype of transgenic NOD-IGF1668 MOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. Thiislets. To this end, the insulitis score was determined in pancreatic
histological sections at 15 and 30 weeks of age. At both ages, NOD
mice that had become diabetic (HG NOD) had lost all of their islets; b-
cells could barely be detected and the inﬁltrate surrounding islets had
mostly disappeared (Figure 3D,F), which precluded the quantiﬁcations is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: b-Cell mass is preserved in NOD-IGF1 transgenic mice. (A) Immunohistochemical detection of insulin (brown) in pancreas from 4-week-old NOD and NOD-IGF1 mice
(n ¼ 6/group). Original magniﬁcation: 20 (pancreas, scale bar: 500 mm) and 400 (islets, scale bar: 50 mm). (BeC) Quantiﬁcation of b-cell mass (B) and number of islets/
pancreatic area (C) in 4-week-old NOD and NOD-IGF1 mice (n ¼ 6/group). (DeG) Immunohistochemical detection of insulin (D, F) and b-cell mass quantiﬁcation (E, G) in
normoglycemic NOD (NOD NG), hyperglycemic NOD (NOD HG), and NOD-IGF1 mice aged 15 and 30 weeks, respectively (n ¼ 3e7/group). Original magniﬁcation 400 (scale bar:
50 mm). (H) Double immunostaining for insulin (red) and Ki67 (green) of islets from 4-week-old NOD and NOD-IGF1 mice (n ¼ 5/group). Blue, nuclei. Arrowheads indicate Ki67þ
b-cells. Original magniﬁcation 400 (scale bar: 50 mm). The histogram depicts the quantiﬁcation of the % of Ki67 positive b-cells. (I) TUNEL staining (green) of islets from 8-
week-old NOD and NOD-IGF1 mice (n ¼ 6/group). Non-b cells were immunostained with anti-glucagon, anti-somatostatin, and anti-pancreatic polypeptide cocktail (red). Blue,
nuclei. Arrowheads indicate TUNELþ b cells. Original magniﬁcation 400 (scale bar: 50 mm). The histogram depicts the quantiﬁcation of the number of TUNEL positive b-cells in
these islets (n ¼ 6/group). Results are expressed as mean  SEM. *P < 0.05 vs. NOD NG; #P < 0.05 vs. NOD HG.
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Figure 4: Overexpression of IGF1 in b-cells prevents immune inﬁltration of NOD islets. (A) Insulitis score in 15 and 30-week-old NOD and NOD-IGF1 mice (n ¼ 3e6/group).
(B) Immunohistochemical detection of Mac-2 (brown) in islets from 15-week-old normoglycemic NOD (NOD NG) and NOD-IGF1 mice (n ¼ 5/group). Original magniﬁcation 200
(scale bar: 50 mm), insets 1000 (scale bar: 25 mm). (CeE) Gene expression in islets from 15-week-old NOD NG and NOD-IGF1 mice. (C) Relative expression of molecules that
participate in antigen presentation and activation of immune cells. (D) Relative gene expression of chemokines known to be involved in homing of diabetogenic T-cell to the
pancreas or (E) in promoting inﬂammation. b2-m: b2-microglobulin; H2-Aa: histocompatibility 2, class II antigen A, alpha; B7.1: CD80 antigen; and B7.2: CD86 antigen; Mip-1a:
macrophage inﬂammatory protein 1a; Mip-1b: macrophage inﬂammatory protein 1b; Mig: monokine induced by interferon-g; Ip-10: interferon-g-induced protein 10; Rantes:
regulated on activation normal T-cell expressed and secreted; Ifn-g: interferon-g; Tnf-a: tumor necrosis factor a; Il-1b: interleukin 1b. Results are expressed as mean  SEM. (F)
Immunohistochemical detection of Foxp3 (brown) in islets from 15-week-old NOD NG (n ¼ 5) and NOD-IGF1 mice (n ¼ 8). Original magniﬁcation 400 (scale bar: 50 mm).
Histogram depicts the quantiﬁcation of the number of Foxp3 positive cells/islet area. The dotted line deﬁnes islet contour. *P < 0.05 vs. NOD NG. NA, Non-available.
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of the insulitis score in these animals (Figure 4A). Nevertheless, NOD
mice that had not developed overt hyperglycemia (NG NOD) had
extensive islet inﬁltration (Figure 3D,F), with over 50% (15 weeks of
age) or 80% (30 weeks of age) of islets showing severe insulitis
(Figure 4A). In contrast, at least 60% of the islets from 15- and,
remarkably, 30-week-old NOD-IGF1 mice had no sign of inﬁltration
(Figures 3D,F and 4A). Moreover, Mac-2 immunostaining revealed
decreased inﬁltration by macrophages in the islets of NOD-IGF1
transgenic mice compared to normoglycemic NOD mice at 15 weeks
of age (Figure 4B).
Subsequently, using qPCR, we evaluated the expression of genes
involved in the inﬂammatory process leading to b-cell damage. As it
was not feasible to isolate islets from diabetic NOD mice (vide supra),
the analysis was performed in normoglycemic (NG NOD) animals; as
these islets were severely inﬁltrated by 15 weeks of age (Figures 3D
and 4A). In comparison to NG NOD mice, NOD-IGF1 animals showed
diminished expression of the b2-microglobulin (b2-m) and H2-Aa genes
(Figure 4C), which encode for the major histocompatibility complex
(MHC) class I and class II antigens, respectively. NOD-IGF1 also showed
reduced expression of the costimulatory receptors B7.1 (CD80) and
B7.2 (CD86) (Figure 4C). To evaluate the possible contribution of inﬁl-
trating immune cells to the observed changes in the proﬁle of islet gene
expression, several approaches were undertaken. First, we analyzed
the expression of MHC molecules in islets obtained from 8-week-old
animals. At this age, the degree of inﬁltration is low and very similar in
NOD and NOD-IGF1 mice (Supplemental Figure 3A and B), and differ-
ences in gene expression can be attributed mostly to phenotypic dif-
ferences in b-cells. The expression of b2-m was lower in NOD-IGF1
islets than in non-transgenic NOD islets, although the decrease did
not reach statistical signiﬁcance (Supplemental Figure 3C). On the other
hand, there was no apparent difference in the expression of H2-Aa
(Supplemental Figure 3C). As a second approach, we cultivated islets
obtained from NOD and NOD-IGF1 animals for 40 h to deplete them of
inﬁltrating cells by spontaneous extrusion of leukocytes [34e37].
Conﬁrming this separation, Ins1 expression was detected preferentially
in islets and Cd45 preferentially in cells present in the culture media
(Supplemental Figure 3D). When b2-m and H2-Aa were analyzed in the
immune cell-depleted islets, a statistically signiﬁcant decrease in the
expression of b2-m was observed in the islets obtained from NOD-IGF1
mice, and a non-statistically signiﬁcant decrease (P ¼ 0.09) was
recorded in the expression of H2-Aa (Supplemental Figure 3E). In
addition, in NOD-IGF1 transgenic animals, we documented a decrease
of at least 50% in the expression of several genes that encode che-
mokines key for the homing of effector T cells to islets, such as
macrophage inﬂammatory protein 1a (Mip-1a) and 1b (Mip-1b), a
monokine induced by interferon-g (Mig), interferon-g-induced protein
10 (Ip-10) and regulated on activation normal T-cell expressed and
secreted (Rantes) (Figure 4D). Similarly, the expression of the main
inﬂammatory cytokines secreted by effector T-cells, interferon-g (Ifn-
g), tumor necrosis factor a (Tnf-a), and interleukin 1b (Il-1b) was also
lower in NOD-IGF1 islets (Figure 4E). At 15 weeks of age, Foxp3 im-
munostaining revealed increased inﬁltration of NOD-IGF1 transgenic
islets by regulatory T cells (Figure 4F). Altogether, these results suggest
that local overexpression of IGF1 manages to halt the immune process
that mediates destruction of b-cells in the NOD model.
3.4. AAV8-mediated speciﬁc expression of IGF1 in the pancreas
The results obtained in transgenic NOD mice provided solid proof-of-
concept that IGF1 expression speciﬁcally in b-cells could protect
from autoimmune diabetes development, underscoring the therapeutic
potential of IGF1. Therefore, we evaluated if IGF1 was also capable ofMOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comprotecting against diabetes following gene transfer of the IGF1 coding
sequence to the pancreas of juvenile and adult NOD mice by means of
AAV vectors.
To maximize the number of cells that would supply IGF1 to islets in a
paracrine/autocrine manner, our gene therapy approach requires the
use of a strong ubiquitous promoter to drive IGF1 expression as well as
an AAV serotype that can deliver the therapeutic construct to both
endocrine and acinar cells after intraductal administration. This
strategy is of great interest considering that b-cells are selectively
destroyed by the immune system in T1D. To assess in vivo trans-
duction efﬁciency in NOD mouse pancreas, 1012 vector genomes (vg)
of AAV8 vectors encoding for GFP under control of the ubiquitous CAG
promoter (AAV8-CAG-GFP) were administered to the pancreatic duct of
4-week-old female NOD mice. Robust transduction of both endocrine
and exocrine pancreas was observed 2 weeks post-injection
(Figure 5A,B). However, the use of the ubiquitous CAG promoter also
led to production of GFP in the liver and heart (Figure 5C), in agreement
with previous reports in other mouse strains [20,22,23].
To prevent transgene expression in liver and heart and restrict AAV8-
mediated IGF1 overexpression to pancreas, we took advantage of
microRNAs (miRs) [26]. Target sequences for liver-speciﬁc miR-122a
and heart-speciﬁc miR-1, which selectively detarget transgene
expression from liver and heart when included into AAV vectors [27],
were added in tandem repeats of 4 copies to the 30-UTR of the IGF1
expression cassette (AAV8-IGF1-dmiRT) (Figure 5D). Despite the
metabolic alterations, miR-122a and miR-1 expression levels were
normal in liver (Figure 5E) or heart (Figure 5F) of diabetic NOD females,
and the disease did not induce expression of these miRs in pancreas
(Figure 5E,F). To validate our detargeting strategy, 1012 vg of IGF1-
encoding AAV8 vectors containing or not miRNA target sequences
(AAV8-IGF1-dmiRT and AAV8-IGF1, respectively) were intraductally
delivered to 4-week-old NOD females. Animals injected with the same
dose of non-coding AAV8 (AAV8-NULL, Figure 5D) served as controls.
One month after vector administration, pancreatic Igf1 mRNA levels
were similar in those animals that received AAV8-IGF1-dmiRT or
AAV8-IGF1 (Figure 5G). In liver and heart, however, IGF1 expression
differed considerably between both groups. While in the AAV8-IGF1-
treated group Igf1 expression was high in both organs, the inclusion
of miR-122a and miR-1 sequences in the transgene cassette abolished
expression in liver and heart (Figure 5G). Indeed, animals treated with
AAV8-IGF1 vectors showed a tendency towards an increase in IGF1
levels in serum which was not present in the AAV8-IGF1-dmiRT treated
group (Figure 5H). All mice showed similar vector genome copy
numbers in all tissues (Supplemental Figure 4A and B), further con-
ﬁrming that the observed differences in Igf1 levels were due to miRT-
mediated speciﬁc silencing of transgene expression.
Six months after AAV delivery, miR-122a and miR-1 levels were similar
in liver and heart of NOD mice injected with AAV8-IGF1-dmiRT or AAV8-
NULL (Supplemental Figure 4C and D). Accordingly, hepatic expression
of several of miR-122a-target genes was unaffected by administration
of vectors containing miRT sequences (Supplemental Figure 4E), nor
was serum cholesterol (Supplemental Figure 4F), allegedly regulated by
miR-122a [38]. Altogether, these results suggested that long-term
prevention of IGF1 overexpression in off-target tissues by inclusion of
miRT sequences in the AAV expression cassette did not repress
endogenous microRNAs by competitive inhibition.
3.5. AAV-mediated pancreatic Igf1 expression protects against
autoimmune diabetes in NOD mice
To determine whether pancreatic Igf1 expression could prevent dia-
betes development in NOD mice, 1012 vg of AAV8-IGF1-dmiRT oren access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 671
Figure 5: AAV vectors can speciﬁcally transduce the pancreas. (A) Immunohistochemical detection of GFP (green) and insulin (red) in pancreas 2 weeks after intraductal
administration of AAV8-CAG-GFP (1012 vg) to 4-week-old NOD mice (n ¼ 4/group). Original magniﬁcation 400 (scale bar: 50 mm). (B, C) GFP immunostaining (green) in exocrine
pancreas (B) and liver and heart (C) in the same cohort of mice. Original magniﬁcation 200 (scale bar: 50 mm). (D) Schematic representation (not to scale) of the different AAV
genomes. ITR: Inverted Terminal Repeats; CAG: hybrid cytomegalovirus enhancer/chicken b-actin promoter; mIGF1: murine Igf1 cDNA corresponding to IGF1Ea propeptide;
miRT-122a: microRNA-122a target sequence (4 copies); miRT-1: microRNA-1 target sequence (4 copies); pA: polyadenylation signal. dmiRT refers to incorporation of both miRNA-
122a and miRNA-1target sequences. The schematic representation is not to scale. (E, F) Expression of miR-122a (E) and miR-1 (F) was quantiﬁed in either normoglycemic (NG) (8-
week-old) or hyperglycemic (HG) (24 week-old) NOD females. ND, Non-Detected; (n ¼ 4e6/group). (G) Igf1 gene expression in pancreas, liver and heart of NOD mice 1 month
after intraductal administration of 1012 vg of AAV8-IGF1-dmiRT, AAV8-IGF1 or AAV8-NULL to 4-week-old NOD mice (n ¼ 4e6/group). (H) Serum IGF1 levels in the same cohort
than in G (n ¼ 3e5/group). Results are expressed as mean  SEM. *P < 0.05 vs. AAV8-NULL; #P < 0.05 vs. AAV8-IGF1.
Original Article
672 MOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Figure 6: Intraductal delivery of AAV8-IGF1-dmiRT vectors protects against autoimmune diabetes in NOD mice. (A) Cumulative incidence of diabetes over a period of 28
weeks in non-treated NOD mice (n ¼ 34) or NOD mice treated at 4 weeks of age with AAV8-NULL (n ¼ 10) or AAV8-IGF1-dmiRT (n ¼ 15). (B) Cumulative incidence of diabetes
over a period of 28 weeks in non-treated NOD mice (n ¼ 34) or NOD mice treated at 11 weeks of age with either AAV8-NULL (n ¼ 16) or AAV8-IGF1-dmiRT (n ¼ 17). (C)
Immunohistochemical analysis of pancreas sections to detect IGF1 in 28-week-old NOD mice treated at 4 weeks or 11 weeks with either AAV8-NULL or AAV8-IGF1-dmiRT (n ¼ 4e
5/group). Original magniﬁcation 400 (scale bar: 50 mm). (D, E) Igf1 gene expression analysis in islets (D) and total pancreas (E) from 28-week-old mice treated at 4 weeks of age
(n ¼ 5e8/group). (F) IGF1 levels in serum from normoglycemic 28-week-old mice treated at 4 weeks of age with AAV8-NULL (n ¼ 4) or AAV8-IGF1-dmiRT (n ¼ 10). Results are
expressed as mean  SEM. *P < 0.05 vs. AAV8-NULL.
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Original ArticleAAV8-NULL were intraductally delivered to 4-week-old pre-diabetic
NOD females. At this age, islet inﬁltration by mononuclear cells
(insulitis) was negligible (Supplemental Figure 5A). Following vector
administration, glycemia was monitored biweekly in all treatment
groups up to 28 weeks of age. By week 28, 80% of NOD mice treated
with AAV8-IGF1-dmiRT vectors remained normoglycemic (Figure 6A),
indicating they had been protected from disease development by
therapeutic vector administration. Moreover, in the remaining 20% of
AAV8-IGF1-dmiRT-treated mice that did develop hyperglycemia, dia-
betes onset was delayed by 6e8 weeks (Figure 6A). In contrast, AAV8-
NULL-injected NOD females behaved similarly to untreated NOD ani-
mals, showing 60e65% accumulative incidence of diabetes by week
28 (Figure 6A).
After having tested Igf1 delivery at very early ages and getting positive
results, treatment efﬁcacy in stopping diabetes progression was
evaluated at a more advanced stage of the pathology by intraductally
delivering 1012 vg of AAV8-IGF1-dmiRT to 11-week-old NOD mice.
Diabetes onset typically occurs close to this age in NOD females [33],
whose pancreas showed inﬁltration and b-cell destruction in>50% of
their islets (Supplemental Figure 5B and vide infra). Despite the
advanced disease progression, treatment at 11 weeks also resulted in
marked reduction of diabetes incidence. More than 75% of AAV8-IGF1-
dmiRT-treated mice remained normoglycemic at 28 weeks of age
while 50% of mice that received Null vectors became hyperglycemic
(Figure 6B). Overall, these results indicate that AAV-mediated
pancreatic overexpression of IGF1 protected NOD mice against dia-
betes development even when the pathogenic mechanisms respon-
sible for disease onset and progression were already established.
3.6. Long-term pancreatic IGF1 expression after AAV-mediated
gene transfer
Long-term IGF1 expression was evaluated at the end of the follow-up
period, i.e. in 28-week-old mice. Histological analysis suggested the
majority of cells that overexpressed IGF1 within the islets of AAV8-
IGF1-dmiRT-treated mice at either 4 or 11 weeks of age were b-
cells (Figure 6C). Double immunostaining conﬁrmed the identity of
most IGF1-producing cells as insulin positive b-cells (Supplemental
Figure 6). IGF1 production was not easily detected in exocrine cells
(Figure 6C and Supplemental Figure 6), probably due to rapid excretion
of the factor from these cells, as opposed to its accumulation in the
secretory granules of b-cells. As expected, AAV8-NULL-injected ani-
mals had very few insulin positive cells and showed no IGF1 production
in either the endocrine or exocrine pancreas (Figure 6C and
Supplemental Figure 6). Moreover, double glucagon and insulin im-
munostaining of AAV8-IGF1-dmiRT-treated pancreas showed islets
with normal distribution of different endocrine cells, with insulin-
expressing cells located in the core of the islet and glucagon-
expressing cells in the periphery (Supplemental Figure 7). In
contrast, AAV8-NULL-treated mice showed islet destruction and lack of
insulin-expressing cells (Supplemental Figures 6 and 7). Quantiﬁcation
of IGF1 mRNA levels in islets obtained from 28-week-old NOD mice
treated with AAV8-IGF1-dmiRT at the age of 4 weeks showed 30-fold
increase in Igf1 mRNA levels over the values obtained in islets of Null-
injected animals (Figure 6D). When the quantiﬁcation was performed
on RNA isolated from whole pancreas, a 10-fold increase was docu-
mented (Figure 6E). These levels of expression were very similar to
those observed 1 month after vector administration (Figure 5G), sug-
gesting that there had been no loss of transgene expression over time.
Similar to the observations made in transgenic NOD mice over-
expressing IGF1 speciﬁcally in b-cells (Figure 1D), no differences were
observed between groups in the levels of circulating IGF1 (Figure 6F).674 MOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. ThiAltogether, these results suggested that prevention of diabetes in
AAV8-IGF1-dmiRT-treated NOD mice was mediated by autocrine/
paracrine secretion of IGF1 in the pancreas.
3.7. AAV-mediated pancreatic expression of IGF1 preserves
pancreatic b-cell mass and insulinemia
Insulin immunostaining was performed to evaluate b-cell mass at 28
weeks of age in different cohorts of NOD mice (Figure 7A). At 4 weeks,
untreated pre-diabetic NOD mice had islets with normal appearance,
and there was no sign of islet inﬁltration (Figure 3A and Supplemental
Figure 5A). At 8 weeks of age, when insulitis is already detectable in
the NOD model (vide infra), b-cell mass showed no differences be-
tween AAV8-NULL-injected or AAV8-IGF1-dmiRT-treated NOD animals
(Figure 7B). Accordingly, both cohorts had comparable levels of
circulating insulin (Figure 7C). Similar values of b-cell mass and
insulinemia were documented in untreated 11-week-old NOD mice
(Figure 7D,E). Secondary to diabetes development, however, 28-week-
old NOD mice injected with AAV8-NULL vectors at either 4 or 11 weeks
of age showed almost complete b-cell loss (Figure 7B,D); very few
islets and insulin positive b-cells were observed in histological sec-
tions (Figure 7A), and insulin was undetectable in serum (Figure 7C,E).
In contrast, 28-week-old NOD mice treated at either 4 or 11 weeks of
age with therapeutic AAV8-IGF1-dmiRT vectors showed preservation
of b-cells (Figure 7A,B and D). This maintenance of the b-cell mass did
not seem to be sustained by a signiﬁcant increase in b-cell replication
in AAV8-IGF1-dmiRT-treated NOD animals, as evidenced by the
quantiﬁcation of Ki67 positive cells 4 weeks after vector delivery
(Supplemental Figure 8). The b-cell mass documented in IGF1-treated
animals was similar to that previously reported for immunodeﬁcient
NOD-SCID mice of similar age in which the immune-mediated
destruction of b-cells does not occur [39]. Accordingly, AAV8-IGF1-
dmiRT-treated NOD mice had preserved insulinemia (Figure 7C,E).
3.8. AAV-mediated pancreatic expression of IGF1 blocks immune-
mediated b-cell destruction
At 4 weeks of age, no sign of inﬁltration was observed in any of the
islets analyzed, and NOD mice were considered insulitits-free
(Figure 8A and Supplemental Figure 5A). However, by 8 weeks, a
similar extent of islet inﬁltration become apparent in NOD mice
administered with either NULL or AAV8-IGF1-dmiRT vectors:w20% of
islets showed some degree of insulitis at this age (Figure 8A). At 11
weeks, non-treated NOD mice hadw50% of islets inﬁltrated,w20%
of which showed severe insulitis (Figure 8B and Supplemental
Figure 5B). By 28 weeks, animals injected at either 4 or 11 weeks
with AAV8-NULL vectors that became diabetic had lost all their islets:
b-cells were barely detectable and the inﬁltrate surrounding islets had
mostly disappeared (Figure 7A), precluding insulitis scoring
(Figure 8A,B). AAV8-NULL-injected NOD mice that had not developed
overt hyperglycemia by 28 weeks had, nevertheless, extensive
(>80%) islet inﬁltration, withw70% of islets showing severe insulitis
(Figure 8C). In contrast, 28-week-old NOD mice that received IGF1-
encoding vectors at 11 weeks had at least 50% of insulitis-free is-
lets; the percentage was slightly higher (w60%) in animals receiving
the therapeutic vector at 4 weeks (Figure 8A,B). In animals treated with
AAV8-IGF1-dmiRT at 11 weeks, the insulitis score at 28 weeks
resembled that observed pre-treatment, suggesting that AAV-mediated
local expression of IGF1 had managed to halt the immune process that
leads to b-cell loss.
Then, we evaluated by qPCR the expression of genes involved in the
immune process leading to b-cell death. As it is not feasible to isolate
islets from 28-week-old diabetic AAV8-NULL-injected NOD mice, thes is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: Pancreatic IGF1 expression preserves b-cell mass and circulating insulin levels. (A) Immunohistochemical detection of insulin (brown) in pancreas from 28-week-
old mice treated at 4 weeks or 11 weeks of age with either AAV8-NULL (n ¼ 3e4) or AAV8-IGF1-dmiRT (n ¼ 4e5). Insulin positive b-cells could barely be detected in AAV8-NULL-
treated mice. Red arrowheads indicate islets. Original magniﬁcation 20 (scale bar: 500 mm), insets 400 (scale bar: 50 mm). (B) Quantiﬁcation of the b-cell mass in 8 or 28-
week-old NOD mice treated with AAV8-NULL (n ¼ 3e4) or AAV8-IGF1-dmiRT (n ¼ 5) vectors at 4 weeks of age. (C) Serum insulin levels in fed conditions in the same cohorts of
animals as in B. AAV8-NULL (n ¼ 3e4); AAV8-IGF1-dmiRT (n ¼ 5). (D) Quantiﬁcation of b-cell mass in non-treated 11-week-old NOD mice (n ¼ 4) or 28-week-old NOD mice
treated with AAV8-NULL (n ¼ 3) or AAV8-IGF1-dmiRT (n ¼ 4) at 11 weeks of age. (E) Serum insulin levels in fed conditions in the same experimental cohorts as in D. Non-treated
(n ¼ 7); AAV8-NULL (n ¼ 4); AAV8-IGF1-dmiRT (n ¼ 10). Results are expressed as mean  SEM. *P < 0.05 vs. AAV8-NULL. ND, Non-detected.
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Figure 8: Pancreatic overexpression of IGF1 prevents immune inﬁltration of islets. (A) Insulitis score in non-treated 4-week-old NOD mice (n ¼ 6), and 8 or 28-week-old
NOD mice treated at 4 weeks with either AAV8-NULL (n ¼ 4) or AAV8-IGF1-dmiRT (n ¼ 5). (B) Insulitis score in non-treated 11-week-old NOD mice (n ¼ 6) and 28-week-old NOD
mice treated at 11 weeks with AAV8-NULL (n ¼ 4) and AAV8-IGF1-dmiRT (n ¼ 4). (C) Insulitis score in 28-week-old NOD mice treated with AAV8-NULL (n ¼ 3) at 4 weeks that
remained normoglycemic (NG). (DeF) Gene expression in islets from normoglycemic 28-week-old NOD mice treated with AAV8-NULL or AAV8-IGF1-dmiRT at 4 weeks. (D)
Relative expression of molecules that participate in antigen presentation and immune cell activation. (E) Relative gene expression of chemokines known to be involved in homing of
diabetogenic T-cell to the pancreas or (F) promoting inﬂammation. b2-m: b2-microglobulin; H2-Aa: histocompatibility 2, class II antigen A, alpha; B7.1: CD80 antigen; and B7.2:
CD86 antigen; Mip-1a: macrophage inﬂammatory protein 1a; Mip-1b: macrophage inﬂammatory protein 1b; Mig: monokine induced by interferon-g; Ip-10: interferon-g-induced
protein 10; Rantes: regulated on activation normal T-cell expressed and secreted; Ifn-g: interferon-g; Tnf-a: tumor necrosis factor a; Il-1b: interleukin 1b. AAV8-NULL (n ¼ 4);
AAV8-IGF1-dmiRT (n ¼ 6). Results are expressed as mean  SEM. *P < 0.05 vs. AAV8-NULL. NA, Non-available.
Original Articleanalysis was performed in normoglycemic (NG) animals administered
with NULL vectors at 4 weeks; as previously demonstrated the islets of
these mice were severely inﬁltrated by 28 weeks (Figure 8C). In
comparison to NG AAV8-NULL NOD mice, NG NOD mice that received676 MOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. Thithe therapeutic AAV8-IGF1-dmiRT vector showed diminished expres-
sion of the b2-m and H2-Aa genes, as well as reduced expression of
the costimulatory receptors B7.1 and B7.2 (Figure 8D). In addition, we
documented a decrease of at least 50% in the expression of Mip-1as is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Mip-1b, Mig, IP-10, and Rantes (Figure 8E). Similarly, expression
of the main inﬂammatory cytokines secreted by effector T-cells, Ifn-g,
Tnf-a, and Il-1b was also lower in islets from AAV8-IGF1-dmiRT-
treated NOD mice (Figure 8F). Altogether, these observations indicate
that AAV-mediated IGF1 pancreatic overexpression protected from
diabetes development by limiting the autoimmune attack against b-
cells. Furthermore, observations made following treatment of adult
animals suggest that the expression of IGF1 during embryonic devel-
opment is not a requirement to achieve this protection.
4. DISCUSSION
Here we show, ﬁrst in a transgenic animal model and then through
AAV-mediated pancreatic gene transfer, that local IGF1 production
protects NOD mice against spontaneous immune-mediated b-cell loss
and development of hyperglycemia. Thus, we demonstrate the ther-
apeutic potential of a gene therapy that speciﬁcally overexpresses IGF1
in the pancreas to modify disease progression in autoimmune
diabetes.
The overexpression of IGF1 in NOD islets completely protected from
development of spontaneous autoimmune diabetes. Transgenic NOD-
IGF1 mice had normal levels of insulin in circulation and were glucose
tolerant. Also, and in contrast to their diabetic NOD counterparts, NOD-
IGF1 animals had normal levels of serum triglycerides, free-fatty acids,
and b-hydroxybutyrate, indicative of normal energy metabolism. IGF1
overexpression clearly protected b-cells. While non-transgenic NOD
mice that became hyperglycemic had lost almost all their b-cells by 15
weeks of age, NOD-IGF1 mice showed preserved b-cell mass up to the
end of the follow-up period (30 weeks). By this age, >70% of NOD
animals had overt diabetes. Noticeably, 4-week-old NOD-IGF1 mice
already showed greater b-cell mass than non-transgenic NOD litter-
mates. This early-age increase in the b-cell mass was associated with
an increased number of islets, which were otherwise of normal size
and structure, showing normal distribution of the different endocrine
cells. Such an increase in b-cell mass was not observed in RIP-IGF1
transgenic mice with other genetic backgrounds prior to STZ admin-
istration [15e17], suggesting that the increase is relative to the NOD
mouse. Indeed, it has been described that NOD mice have decreased
b-cell mass (w70%) before diabetes onset when compared to NOD/
Scid in which autoimmune diabetes does not occur [40]. Thus, the
overexpression of IGF1 from birth in NOD-IGF1 transgenic mice may be
compensating for this reduction. Moreover, despite IGF1 over-
expression in these mice, we could not ﬁnd any indication of increased
rate of replication in transgenic b-cells. In fact, of all the controllers of
the cell cycle whose expression was analyzed, only p21 expression
was increased in NOD-IGF1 islets. p21 is an inhibitor of cyclin-
dependent kinases, and hence a negative regulator of the cell cycle
[32]. Likely, this increase in p21 compensated for the chronic prom-
itogenic stimuli provided by IGF1, resulting in a normal rate of b-cell
replication in NOD-IGF1 mice. We did, however, observed evidence of
reduced apoptosis in NOD-IGF1 islets. Thus, our current hypothesis is
that this early-age increase in b-cell mass is a consequence of IGF1
expression at the early postnatal period in which the b-cell mass is
reshaped through physiological waves of apoptosis [41].
Several clinical studies have provided evidence of therapeutic beneﬁt,
such as reductions in glycated hemoglobin or insulin requirements,
following administration of high doses of recombinant human IGF1 to
diabetic patients [10e12]. IGF1 systemic treatment however, was
associated with clinically signiﬁcant adverse events attributed to
increased circulating IGF1, such as edema, jaw ache, headache,
tachycardia, and fatigue [42]. In addition, multiple productMOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. This is an op
www.molecularmetabolism.comadministrations were required and therapeutic efﬁcacy was transient
by nature, limited by the short half-life of IGF1 in circulation. To
overcome these limitations, we designed a novel therapeutic strategy
based on AAV-mediated gene transfer to achieve long-lasting, local
production of IGF1 following a single administration of therapeutic
product. AAVs are not associated with any human disease and are
hence regarded as safe vectors for gene therapy, which has encour-
aged their use in an increasing number of clinical trials [18]. Indeed, in
2012 the European Commission granted marketing authorization to
Glybera, an AAV-based therapeutic for the treatment of Lipoprotein
Lipase deﬁciency [43], and other market authorizations are underway.
AAV8 was chosen, because we previously demonstrated this serotype
is very efﬁcient at transducing exocrine and endocrine pancreas [20].
AAV8 also has signiﬁcant tropism for liver and heart, and transduction
of these organs occurs even if the vector is administered locally to
other organs. Given that clinical studies have highlighted the potential
toxicity associated with increased circulating IGF1, we detargeted
expression of IGF1 from these organs by incorporation to our
expression cassette of miRTs for miR-122a and miR-1-miRNAs highly
expressed in liver and heart, respectively. This enabled us to conve-
niently overexpress IGF1 in pancreas while efﬁciently silencing
transgene expression in liver and heart. Importantly, administration of
miRT-containing vectors proved very safe. Six months after AAV8
administration, endogenous miR-1 and miR-122a expression was not
altered, nor was de-repression of miR-122a target genes triggered.
This observation agreed with other studies, indicating that the miR-122
pathway is not affected by AAV vectors containing several copies of
miR-122 miRT [44]. A marked reduction in serum cholesterol has also
been reported when antisense oligonucleotides were used to
sequester miR-122, indicating that cholesterol metabolism is a target
of this miRNA [45]. Six months after delivering our vectors to NOD
mice, however, animals showed normal levels of cholesterol in cir-
culation, further demonstrating that the delivery of miR-122a-
containing AAV vectors did not affect miR-122 physiological functions.
AAV-mediated Igf1 gene transfer to pancreas protected NOD mice
against development of autoimmune diabetes, as evidenced by the
signiﬁcant reduction in the incidence of spontaneous diabetes in the
animals that received therapeutic vector. IGF1-treated mice also
showed preservation of b-cell mass and normal levels of circulating
insulin. Noticeably, as in all previous models, serum IGF1 remained
unaltered. Besides conﬁrming previous observations made in trans-
genic mice, this study also discarded the possibility that the phenotype
described in transgenic models was due to expression of the transgene
during embryonic development and early postnatal life. Also, although
RIP-IGF1 transgenic mice have been backcrossed more than 15 times
onto the NOD background, studies with the AAV platform rule out that
protection from diabetes is related to some resistance gene that has
been carried forward with the transgene from the original background
strain. Although therapeutic beneﬁt following gene transfer was slightly
greater in animals treated at 4 weeks, before the immune process
commences in this model, an unexpected ﬁnding of our study was the
ability of AAV8-IGF1-dmiRT to halt disease progression even when
animals were treated at 11 weeks, an age at which NOD mice treated
with NULL vectors begin to turn hyperglycemic. In NOD mice treated
with AAV8-IGF1-dmiRT at 11 weeks, diabetes incidence at 28 weeks
was 23%, as opposed tow70% orw50% registered in the untreated
or Null-injected groups, respectively.
The mechanisms by which IGF1 exerts its protective action on trans-
genic islets or after AAV-mediated gene delivery have not been fully
elucidated. The observations made after gene transfer argue against
the possibility that the protection against diabetes documented inen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 677
Original Articletransgenic animals was due to an initially greater number of b-cells, as
NOD mice that received AAV8-IGF1-dmiRT vectors had the same b-cell
mass at treatment than untreated NOD mice that became diabetic.
Protection against diabetes cannot be attributed either to systemic
effects of IGF1 on metabolism. NOD-IGF1 mice had normal circulating
levels of IGF1, similar to all the previous transgenic lines in which IGF1
was overexpressed speciﬁcally in b-cells [15e17]. Likewise, AAV8-
IGF1-dmiRT-treated NOD mice had the same IGF1 levels as un-
treated controls.
Protection against diabetes, in theory, could result from a combination
of enhancement of b-cell survival, stimulation of b-cell replication, and
promotion of an immunoprotective milieu within the islet that allows
survival of functional insulin-producing b-cells. IGF1 protects against
apoptosis [46] and has positive effects on b-cell mitogenesis and islet
growth [2,47]. IGF1 stimulates b-cell replication, in particular under
conditions of b-cell damage. We previously demonstrated in RIP-IGF1
transgenic mice with C57Bl/SJL genetic background that b-cell-spe-
ciﬁc IGF1 overexpression protects the b-cell mass through activation of
cyclins that promote mitosis [16]. Noticeably, activation of these cyclins
only occurs upon STZ-induced damage [16]. An obvious increase in b-
cell replication, however, was not detected in the current study, either in
NOD transgenic islets or following gene transfer of Igf1 to the NOD
pancreas. This could argue against a major role of enhanced b-cell
replication in the maintenance of the b-cell mass in the context of
autoimmune diabetes or could reﬂect technical limitations associated
with the detection of replication at speciﬁc time-points. We did, how-
ever, detect reduced apoptosis in the islets of transgenic NOD-IGF1.
Autoimmunity plays a key pathogenic role in the development of dia-
betes in the NOD model; immunodeﬁcient SCID-NOD mice do not
develop overt diabetes [48]. The most striking ﬁnding of our study was
the documentation of a dramatic reduction in the degree of insulitis in
NOD-IGF1 transgenic islets or after Igf1 gene transfer to adult animals.
More than 60% of NOD-IGF1 islets showed no sign of inﬁltration at an
age (30 weeks) at which 80% of non-transgenic NOD islets had severe
insulitis and no remaining b-cells. Similarly, NOD mice that received
IGF1-encoding AAV vectors at either 4 or 11 weeks had at least half of
their islets free of insulitis by 28 weeks of age. In animals treated with
AAV8-IGF1-dmiRT at 11 weeks, the insulitis score at 28 weeks
resembled that observed pre-treatment, suggesting that local
expression of IGF1 had managed to halt the immune process.
In addition, in NOD-IGF1 transgenic mice and in non-transgenic NOD
animals following AAV8-IGF1-dmiRT treatment, we observed a reduc-
tion in the expression of antigen-presenting molecules and chemokines
known to be involved in homing of diabetogenic T-cells to the pancreas
[49,50]. The presence of class I antigen-presenting molecules on b-
cells is key to the activation of diabetogenic T-cells and initiation of b-
cell autoimmune destruction [51e53]. Thus, the documented reduction
in b2-microglobulin and B7 expression could provide an explanation to
the lesser degree of b-cell destruction. This is consistent with other
reports suggesting that IGF1 plays a role in immune evasion in a variety
of cells by down-regulating MHC-I and B7 [54,55]. Expression of genes
associated with antigen presentation through MHC-II, such as H2-Aa,
was also reduced. However, there is controversy regarding whether b-
cells express MHC-II molecules [56]; hence, our observations may result
from reduction in professional APCs, such as islet-inﬁltrating macro-
phages. Besides preventing activation of antigen-speciﬁc immune re-
sponses or recruitment of immune cells to pancreatic islets, it is also
possible that pancreatic IGF1 overexpression acted by modulating the
function of the inﬁltrate. IGF1 receptors are expressed on T-cells, and
regulatory T-cell function and number may be modulated by IGF1
promoting anti-inﬂammatory effects [7,57]. Although a statistically678 MOLECULAR METABOLISM 6 (2017) 664e680  2017 The Authors. Published by Elsevier GmbH. Thisigniﬁcant increase in the number of Foxp3 positive cells was docu-
mented in the islets of NOD-IGF1 transgenic mice, no differences were
observed 4 weeks post vector delivery (data not shown). This apparent
discrepancy is likely the consequence of the difﬁculty in selecting the
proper time-point of quantiﬁcation.
Several preclinical and clinical trials have shown potential efﬁcacy of
immunotherapies in counteracting T1D. For example, administration of
anti-CD3 or anti-CD20 monoclonal antibodies targeting T and B-cells,
respectively, to patients with recent-onset diabetes has shown
beneﬁcial effects on preservation of b-cell function [58,59]. Combined
therapies with Rapamycin and IL-2 to suppress T-cell activation and
enhance tolerance have also effectively treated diabetes in NOD mice
[60], yet clinical studies have yielded conﬂictive results with transient
worsening of b-cell function [61]. Through its immune-modulating,
anti-apoptotic and trophic effects on b-cells, local IGF1 gene trans-
fer offers an attractive alternative to the chronic and systemic modu-
lation of the immune system, potentially associated with life-
threatening risks.
Finally, an important aspect for the clinical translation of the approach
is that the technique used to administer vectors to the pancreas, the
retrograde pancreatic intraductal injection, can be scaled to large
animals and humans [62] through a nonsurgical procedure. Indeed,
endoscopic retrograde cholangiopancreatography (ERCP) [63] is
commonly used in the clinical setting to study and treat problems of
bile and pancreatic ducts. The existence of an established procedure to
reach the human pancreas in a minimally-invasive manner opens the
possibility of safe gene transfer to the pancreas of diabetic patients.
Although a considerable number of therapeutic approaches have been
developed for T1D, efﬁcacy has been limited by systemic toxicity or
limited magnitude and/or duration of therapeutic beneﬁts. Our study
demonstrates that AAV-mediated Igf1 gene transfer, in combination
with miRNA technology, may be an effective way to protect b-cells
from the immune attack in vivo, and highlights the therapeutic potential
of this approach to treat autoimmune diabetes in humans.
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